Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DARA-MVI: Daratumumab for Microvascular Inflammation in Kidney Transplant
NCT07274462Phase 4Active, not recruiting
- Sponsor
- University Hospital Martin
- Start
- Nov 2025
- Primary completion
- Mar 2027
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of daratumumab in microvascular inflammation (MVI), sponsored by University Hospital Martin. Started Nov 2025; status: active, not recruiting.
02
Drugs
daratumumab
03
Conditions
microvascular inflammation (MVI)
Beyond the preview
Go deeper on NCT07274462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07274462.